Cardiac Events and Dynamic Echocardiographic and Electrocardiogram Changes Following Osimertinib Treatment in Lung Cancer
JN Le, JO Gasho, O Peony, A Singh… - Frontiers in …, 2024 - frontiersin.org
Osimertinib is first-line treatment for epidermal growth factor (EGFR)-mutated non-small cell
lung cancer (NSCLC) and has been associated with cardiotoxicity. However, the nature of …
lung cancer (NSCLC) and has been associated with cardiotoxicity. However, the nature of …
Late cardiotoxicity related to HER2-targeted cancer therapy
I Senechal, MS Andres, J Tong, Y Perone… - Cardio-Oncology, 2024 - Springer
Long-term anti-HER2 therapy in metastatic HER2+ cancers is increasing, but data about the
incidence and risk factors for developing late Cancer therapy-related cardiac dysfunction …
incidence and risk factors for developing late Cancer therapy-related cardiac dysfunction …